Darzalex regimen increases survival in multiple myeloma

Data presented by Janssen this week demonstrated that a Darzalex regimen significantly increased progression-free survival in patients with relapsed/refractory multiple myeloma.

Results from the Phase 3 Candor Study shows the addition of Darzalex (daratumumab) to carfilzomib (Kyprolis) and dexamethasone (DKd) compared to carfilzomib and dexamethasone (Kd) alone resulted in a 37% reduction in the risk of progression or death.

Compared to Kd alone, DKd resulted in significantly longer PFS rates and response rates. The primary endpoint was met after a median follow-up of 16.9 months and 16.3 months for the DKd and Kd arms, respectively.

“These data from the Phase 3 Candor study reinforce the growing body of evidence supporting the use of daratumumab-containing regimens in the treatment of multiple myeloma,” said principal investigator Saad Z. Usmani, Division Chief of Plasma Cell Disorders, Levine Cancer Institute.

“The results provide important evidence for this combination regimen in the relapsed and refractory setting, where there is still significant unmet need, especially among lenalidomide refractory patients.”

Candor is an Amgen-sponsored study and is co-funded by Janssen Research & Development. The study included patients who had received 1–3 prior lines of therapy for multiple myeloma.

Of the patients randomised in the study, 42% and 90% had previous exposure to lenalidomide and bortezomib, respectively; 33% were lenalidomide-refractory and 29% were bortezomib-refractory.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...